CHMP recommends marketing authorization of Cosentyx (secukinumab) in adolescents aged 12+ with hidradenitis suppurativa – Novartis
Novartis announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing authorization of Cosentyx (secukinumab) for… read more.
